Director/PDMR Shareholding

Diaceutics PLC
07 March 2024
 

Diaceutics PLC

 

Director / PDMR Shareholding - NED Purchase of Shares

 

 

Belfast and London, 07 March 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announces that on 6 March 2024, Graham Patterson, a Non-Executive Director of Diaceutics, purchased 33,564 ordinary shares at a price of £0.985 per share. As a result of the purchase, Graham Patterson's shareholding in Diaceutics is 33,564 Ordinary Shares representing approximately 0.04% of the Company's issued share capital.

 

Enquiries: 

 

Diaceutics PLC   


Ryan Keeling, Chief Executive Officer  

Nick Roberts, Chief Financial Officer  

 

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com



Stifel Nicolaus Europe Limited (Nomad & Broker) 

Tel: +44 (0)20 7710 7600 

Ben Maddison 


Nick Harland 


Kate Hanshaw




Alma Strategic Communications

Tel: +44(0)20 3405 0205 

Caroline Forde 

diaceutics@almastrategic.com



About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®

 

 

 

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Graham Patterson

2

Reason for notification

  

a.

Position/Status

Non-Executive Director

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.002 each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)


Share purchase:





Price(s)

Volume(s)


£0.985

33,564



d.

Date of the transaction

6 March 2024

e.

Place of the transaction

AIM Market of the London Stock Exchange



 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Diaceutics (DXRX)
UK 100